NEW YORK & SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on June 3, 2024, the Compensation Committee of Zentalis' Board of Directors granted nonqualified stock options to purchase an aggregate of 20,000 shares of the Company's common stock to two newly hired employe ...

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fid ...

WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from ___________________ to ___________________ Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charte ...

[Operational Highlights and Corporate Updates](index=1&type=section&id=Operational%20Highlights%20and%20Corporate%20Updates) Zentalis advances azenosertib through clinical trials, with upcoming data presentations and a new interim CFO appointment - The clinical development plan for azenosertib remains on track, with multiple data readouts anticipated in **H2 2024 and into 2025**, focusing on gynecological and other solid tumors[1](index=1&type=chunk)[3](index=3&type=chunk) - Final results from the Phase 1 study of azenosertib combined with gemcitabine for relapsed or refractory osteosarcoma are slated for presentation at the **2024 ASCO Annual Meeting**[1](index=1&type=chunk)[6](index=6&type=chunk) - Preclinical data presented at **AACR** showed azenosertib's synergistic anti-tumor activity with **KRAS G12C inhibitors**, indicating potential for combination therapies[6](index=6&type=chunk) - Cam Gallagher was appointed as the interim Chief Financial Officer on **April 5, 2024**[7](index=7&type=chunk) [Anticipated Upcoming Milestones](index=2&type=section&id=Anticipated%20Upcoming%20Milestones) The company outlines key clinical and regulatory milestones for azenosertib, targeting the first NDA submission by **2026** - Key pipeline catalysts for **H2 2024** include final results from the Phase 1b azenosertib monotherapy trial, topline data from the Phase 1/2 MAMMOTH trial in platinum-resistant ovarian cancer, and initial data from Phase 1 trials in BRAF mutant metastatic colorectal cancer and azenosertib + ZN-d5 in R/R AML[10](index=10&type=chunk) - Key events for **2025** include topline data from the registration-enabling Phase 2 DENALI study in platinum-resistant ovarian cancer (**1H 2025**), topline data from the registration-enabling Phase 2 TETON study in uterine serous carcinoma (**2H 2025**), and initiation of a registration-enabling trial in platinum-sensitive ovarian cancer[10](index=10&type=chunk) - The company targets its first **New Drug Application (NDA)** submission for azenosertib in a gynecologic malignancy in **2026**[10](index=10&type=chunk) [First Quarter 2024 Financial Results](index=2&type=section&id=First%20Quarter%202024%20Financial%20Results) Zentalis achieved **Q1 2024 net income of $10.1 million** from **$40.6 million in license revenue**, ending with **$489.0 million cash** projected into mid-2026 [Financial Position and Expenses](index=2&type=section&id=Financial%20Position%20and%20Expenses) As of **March 31, 2024**, Zentalis held **$489.0 million** in cash, projecting a runway into mid-2026, with R&D at **$49.6 million** and G&A at **$15.7 million** - The company's cash, cash equivalents, and marketable securities totaled **$489.0 million** as of **March 31, 2024**, projected to fund operations into **mid-2026**[1](index=1&type=chunk)[9](index=9&type=chunk)[11](index=11&type=chunk) Operating Expenses Comparison (Q1 2024 vs Q1 2023) | Expense Category | Q1 2024 (in millions) | Q1 2023 (in millions) | Change (in millions) | | :--- | :--- | :--- | :--- | | Research & Development | $49.6 | $48.6 | +$1.0 | | General & Administrative | $15.7 | $16.4 | -$0.7 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Zentalis reported **Q1 2024 license revenue of $40.6 million**, resulting in a **net income of $10.1 million** or **$0.14 per diluted share** Q1 2024 Statement of Operations Highlights (in thousands, except per share data) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | License Revenue | $40,560 | $0 | | Total Operating Expenses | $65,325 | $64,953 | | Loss from Operations | ($24,765) | ($64,953) | | Net Income (Loss) | $10,040 | ($63,262) | | Diluted EPS | $0.14 | ($1.07) | [Selected Condensed Consolidated Balance Sheet Data](index=6&type=section&id=Selected%20Condensed%20Consolidated%20Balance%20Sheet%20Data) As of **March 31, 2024**, Zentalis reported **total assets of $557.5 million** and **total liabilities of $98.7 million**, with cash increasing to **$489.0 million** Balance Sheet Highlights (in thousands) | Metric | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash, cash equivalents and marketable securities | $488,984 | $482,919 | | Total Assets | $557,479 | $551,688 | | Total Liabilities | $98,708 | $114,297 | | Total Zentalis Equity | $458,771 | $437,391 | [Company and Product Overview](index=3&type=section&id=Company%20and%20Product%20Overview) Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing small molecule cancer therapeutics, with azenosertib as its lead candidate - Azenosertib is a novel, selective, and orally bioavailable **WEE1 inhibitor** that induces cancer cell death by accumulating DNA damage through cell cycle checkpoint disruption[12](index=12&type=chunk) - The lead product candidate, **azenosertib (ZN-c3)**, is undergoing evaluation as both a monotherapy and in combination therapies for advanced solid tumors and hematologic malignancies[13](index=13&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ TO _________ Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-3607803 ...

Exhibit 99.1 Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates Robust azenosertib clinical development plan ongoing and on track with multiple clinical catalysts anticipated, including monotherapy and combination data readouts in gynecological and other cancer types during 2024 Strengthened management team with appointments of Diana Hausman, M.D., as Chief Medical Officer and Kyle Rasbach, Ph.D., Pharm.D., as Chief Business Officer Corporate Updates $483 million cash ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. (Exact name of registrant as specified in its ch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ TO _________ Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-3607803 ...